US CRO Health Decision says the new “Monitor View” module for its HD360 trial management system makes assessing study site performance an easier and more cost effective process.
West has opened its first manufacturing facility in China to meet rising demand but the process has taken since 2006 and been “very tedious”, its president of West Asia Pacific told Outsourcing-Pharma.
The Chao Center for Industrial Pharmacy and contract manufacturing is to donate $360,000 worth of the antibiotic Seromycin to the Global Health Committee’s fight against multidrug rtesistant tuberculosis (MDR-TB) in Cambodia and Ethiopia.
Quintiles has opened its expanded facility near Edinburgh, Scotland, which has doubled its central lab capacity with the intention of improving the CRO’s service offering in Europe.
Portugese CMO Hovione has had its captisol manufacturing contract extended until 2019 in a new agreement with US specialty drugmaker CyDex Pharmaceuticals.
LGC Standards has made the “next logical step” in its “concerted effort” to expand internationally by opening an office in St Petersburg, Russia, less than six months after it moved into China.
Quintiles has targeted Africa as the next non-traditional area to develop new medicines and the opening of its office in Ghana, which is now fully operational, is a major step in this process, Gillian Corken, head of Quintiles in Africa, told Outsourcing-Pharma.
Market intelligence giant IMS Health has extended its KPO market and sales analytics offering and signed a new collaboration deal with Indian IT contracting group Tata Consultancy Services (TCS).
A totally outsourced model of discovery is “probably valid”, according to a report that believes pharma must overhaul its operations because its business model is in danger of becoming “irrelevant”.
Lab Research (LRI) aims to boost its Korean presence in a new agency deal with Safe Chemicals that, CEO Luc Mainville says, will meet growing demand for large molecule contract R&D.
Recruiting patients with rare diseases for clinical trials could become easier if the US Congress passes a bill to allow patients on supplemental security income (SSI) benefits to receive compensation.
Novasep’s API manufacturing facility in Le Mans, France has been certified under the potent compound safety programme run by occupational health and safety specialist SafeBridge Consultants.
QPS’ bioanalytical laboratory in Taiwan is the first in the country to be certified as compliant with good laboratory practice (GLP) standards by the Department of health (DoH), according to unit president Vincent Yen.
Revenues from Pall’s biopharmaceuticals division grew in fiscal 2009, excluding foreign currency changes, with the company benefiting from the “thriving market” for vaccines and expanding adoption of single-use systems.
Quintiles believes there is a “dire need” for trial sites that can raise standards and reduce inefficiencies in the clinical research process and is expanding its Prime Site programme to meet this demand.
Outsourcing to a well known CRO with a good reputation is vital to ensuring that data is well received by regulatory authorities, according to a CEO that just inked a deal for preclinical safety testing.
Orasi Medical claims CROs and pharmas can cut the cost and length of Alzheimer’s trials, and improve accuracy, by using its brain function measuring service, which is now being promoted in Japan.
Dishman is pushing ahead with its international expansion, increasing efforts to win contracts in the US and Japan and nearing completion of a facility Shanghai, China, which is the first it has built outside of India.
Hyderabad, India-based Makro Care says its GCP “helpdesk” website has already proved to be an invaluable information source for contract research organisations (CRO), investigators and pharma trial sponsors.
Biotechs that partner or outsource in emerging markets are better equipped to innovate and prosper, according to research that warns “if you are not in Shanghai, Mumbai, or Dubai, watch out".
The new partnership with Indian CRO Abridge Clinical Research (ACR) is a unique collaboration offering cost efficient and timely trial solutions according to Global Pharmaceutical Services (GPSI) spokesperson Keith Russell.
Russia-based CRO SynRG has cut the time to prepare a detailed proposal from two weeks to two hours, giving the company a competitive advantage over its rivals, and established a presence in the US to target small to mid-sized companies.
Covance says its new clinical development offices in Brazil and Mexico will increase access to treatment-naïve patients and, ultimately, save pharmaceutical sponsors money.
With Lonza and JLL competing over Patheon Outsourcing-Pharma looks at what the CMO offers to a prospective buyer, analysing its global manufacturing capacity and backlog using interactive maps and graphs.
Encorium has outlined plans to specialise in vaccines, which it believes is an area it can be more flexible than big CROs, and inked a swine flu deal as part of $8.7m (€6m) of new contracts.
Transcrip Partners’ “augmentation” solution for contract R&D “differs from the normal consultancy alternative by fielding ‘doers’ who can think strategically and ‘thinkers’ who are happy to get their hands dirty” according to senior partner Paul Branthwaite.
Bangladesh represents a “huge opportunity” to pharma, according to the CEO of Amreteck Pharma who believes that CMOs will be attracted by the low costs, which undercut China, and help the industry grow to $10bn (€6.9m) in 10 years.
US contract services firm PharmaForm has cut its workforce to 65 employees in a restructuring plan that parent company Akela Pharma said optimises its client support infrastructure.
US investment group JLL has described Lonza’s rival offer for Patheon as “a hostile attempt to adversely impact [the Canadian contractor’s] competitive position.”
By acquiring a stake in India-based RSIPL Evotec believes it can offer clients quicker drug development services, an important aspect of coping with attrition, because larger teams of chemists are available in emerging markets.
The biosimilars sector is predicted to be worth $19.4bn (€13.6bn) by 2014, by which time the US will have overtaken Asia as the dominant market, according to a report.
In the next week the Chinese SFDA is expected to approve licences for two locally produced H1N1 vaccines, which unlike some alternatives only require one dose to confer immunity.
Synexus is meeting the rising demand for its services, which it says can dramatically increase recruitment rates, by acquiring clinical trial sites in Poland and is hoping to expand in India soon.
The Californian budget deficit presents a “real risk to future biotech investments”, according to the CEO of BayBio who explained to how the industry now has a difficult relationship with the state.
Pharmaceutical and cosmetics contract manufacturing organisations (CMOs) in India can now claim tax credit on their advertising spend following a recent appeal court victory for US beverage giant Coca-Cola.
Drug development partnering site goBalto’s addition of Latin American clinical sites to its database in a deal with Chilean CRO Clinical Trials Support (CTS) is timely given the pharma and biotech industry’s focus on emerging markets.
Cobra Biomanufacturing’s new Adenovirus manufacturing and process services contract is further evidence of the health of EU biologicals market, according to business development manager Philip Ridley-Smith.
Basel-headquartered Roche has paid fellow Swiss firm Lonza $290m (€203m) for its Singapore biologics plant in a bid to secure long-term manufacturing capacity for biotech cancer drugs.
US software group SourceSolution has signed a co-marketing deal with bioProcessUK they claim will help UK pharma contractors raise their global profiles and find new drug industry clients.
The number of registered clinical trials in Russia slipped in Q2, with the country attracting fewer international sponsors and regulatory inspections than in pervious years.
Researchers have presented a low cost track and trace and authentication system, which they believe could be implemented immediately, to combat counterfeiting in the developing world.
Europe is pulling ahead of the US in research productivity, according to a controversial new study by Washington public policy think tank Health Affairs.
Pfizer’s new $214.8 million (€150m) biotechnology facility in Strangnas, Sweden was inaugurated yesterday, securing the country’s future in the company’s manufacturing network according to global manufacturing president Natale Ricciardi.
Indian CRO Siro Clinpharm has set its sights on the European research market, signing a deal with UK based CambReg that it hopes will offer customers a path through the region’s complex regulations.
US analysis group CRL will set up a new laboratory at Quotient Bioresearch’s facility in Cambridge in the UK, in a collaboration designed to expand the US company’s business on the global stage and extend Quotient's offering.
Canadian contractor Patheon has welcomed the $460m (€321m) takeover offer from Switzerland's Lonza that could, according to some observers, spark a bidding war with rival suitor, US group JLL Patheon Holdings.
The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has ordered the recall of 100 batches of drugs sold by generics firm Karib Kem Pharm.
GEA Lyophil, part of GEA Pharma Systems, has won a contract to supply Chinjese drugmaker Zheijang Hisun Pharmaceutical with freeze drying systems and automatic loading units.